Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals has released its 2025 annual report, outlining progress in its pipeline of drug therapies aimed at neurodevelopmental disabilities and other serious neurological conditions with substantial unmet need. The report also details the company’s governance structure, executive team and environmental, social and governance framework, signaling continued institutional maturation that may be important for investors and stakeholders tracking its long‑term strategic execution.
Financial statements and accompanying notes in the report provide a comprehensive view of Neuren’s current financial position and capital allocation to research and development. The inclusion of an independent auditor’s report and additional disclosures underscores a focus on transparency and regulatory compliance as the company advances multiple programs toward potential commercialization.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing novel drug therapies for serious neurological conditions arising from genetic abnormalities or brain injury. Headquartered in Melbourne and incorporated in New Zealand, the company is listed on the ASX under the ticker NEU and targets disorders with no or limited approved treatment options.
Average Trading Volume: 540,264
Technical Sentiment Signal: Sell
Current Market Cap: A$1.57B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.